Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Linaclotide treatment reduces endometriosis-associated vaginal hyperalgesia and mechanical allodynia through viscerovisceral cross-talk.

Ge P, Ren J, Harrington AM, Grundy L, Castro J, Brierley SM, Hannig G.

Pain. 2019 Nov;160(11):2566-2579. doi: 10.1097/j.pain.0000000000001657.

PMID:
31335750
2.

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.

Grundy L, Harrington AM, Castro J, Garcia-Caraballo S, Deiteren A, Maddern J, Rychkov GY, Ge P, Peters S, Feil R, Miller P, Ghetti A, Hannig G, Kurtz CB, Silos-Santiago I, Brierley SM.

JCI Insight. 2018 Oct 4;3(19). pii: 121841. doi: 10.1172/jci.insight.121841.

3.

Linaclotide inhibits colonic and urinary bladder hypersensitivity in adult female rats following unpredictable neonatal stress.

Ligon C, Mohammadi E, Ge P, Hannig G, Higgins C, Greenwood-Van Meerveld B.

Neurogastroenterol Motil. 2018 Oct;30(10):e13375. doi: 10.1111/nmo.13375. Epub 2018 May 24.

PMID:
29797376
4.

Linaclotide Attenuates Visceral Organ Crosstalk: Role of Guanylate Cyclase-C Activation in Reversing Bladder-Colon Cross-Sensitization.

Mohammadi EN, Ligon CO, Silos-Santiago A, Ge P, Kurtz C, Higgins C, Hannig G, Greenwood-Van Meerveld B.

J Pharmacol Exp Ther. 2018 Aug;366(2):274-281. doi: 10.1124/jpet.118.248567. Epub 2018 May 21.

5.

Guanylate cyclase 2C agonism corrects CFTR mutants.

Arora K, Huang Y, Mun K, Yarlagadda S, Sundaram N, Kessler MM, Hannig G, Kurtz CB, Silos-Santiago I, Helmrath M, Palermo JJ, Clancy JP, Steinbrecher KA, Naren AP.

JCI Insight. 2017 Oct 5;2(19). pii: 93686. doi: 10.1172/jci.insight.93686.

6.

Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.

Ahsan MK, Tchernychev B, Kessler MM, Solinga RM, Arthur D, Linde CI, Silos-Santiago I, Hannig G, Ameen NA.

Physiol Rep. 2017 Jun;5(11). pii: e13299. doi: 10.14814/phy2.13299.

7.

The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes.

Ge P, Navarro ID, Kessler MM, Bernier SG, Perl NR, Sarno R, Masferrer J, Hannig G, Stamer WD.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1317-26. doi: 10.1167/iovs.15-18958.

8.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.

Tchernychev B, Ge P, Kessler MM, Solinga RM, Wachtel D, Tobin JV, Thomas SR, Lunte CE, Fretzen A, Hannig G, Bryant AP, Kurtz CB, Currie MG, Silos-Santiago I.

J Pharmacol Exp Ther. 2015 Oct;355(1):48-56. doi: 10.1124/jpet.115.224329. Epub 2015 Jul 27.

PMID:
26216942
9.

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.

Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I.

Front Mol Neurosci. 2014 Apr 16;7:31. doi: 10.3389/fnmol.2014.00031. eCollection 2014. Review.

10.

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, Cohen MB, MacDougall JE, Lavins BJ, Kurtz CB, Silos-Santiago I, Johnston JM, Currie MG, Blackshaw LA, Brierley SM.

Gastroenterology. 2013 Dec;145(6):1334-46.e1-11. doi: 10.1053/j.gastro.2013.08.017. Epub 2013 Aug 16.

11.

Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.

Silos-Santiago I, Hannig G, Eutamene H, Ustinova EE, Bernier SG, Ge P, Graul C, Jacobson S, Jin H, Liong E, Kessler MM, Reza T, Rivers S, Shea C, Tchernychev B, Bryant AP, Kurtz CB, Bueno L, Pezzone MA, Currie MG.

Pain. 2013 Sep;154(9):1820-30. doi: 10.1016/j.pain.2013.05.044. Epub 2013 Jun 5.

12.

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG.

J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22.

PMID:
23090647
13.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Mahajan-Miklos S, Pierce CM, Solinga RM, Sun LJ, Tobin JV, Kurtz CB, Currie MG.

Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35. doi: 10.1016/j.ejphar.2010.09.019. Epub 2010 Sep 20.

PMID:
20863829
14.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG.

Life Sci. 2010 May 8;86(19-20):760-5. doi: 10.1016/j.lfs.2010.03.015. Epub 2010 Mar 20.

PMID:
20307554
15.

Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists.

Evindar G, Bernier SG, Doyle E, Kavarana MJ, Satz AL, Lorusso J, Blanchette HS, Saha AK, Hannig G, Morgan BA, Westlin WF.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4. doi: 10.1016/j.bmcl.2010.02.098. Epub 2010 Mar 3.

PMID:
20304639
16.

Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2.

Arico-Muendel CC, Benjamin DR, Caiazzo TM, Centrella PA, Contonio BD, Cook CM, Doyle EG, Hannig G, Labenski MT, Searle LL, Lind K, Morgan BA, Olson G, Paradise CL, Self C, Skinner SR, Sluboski B, Svendsen JL, Thompson CD, Westlin W, White KF.

J Med Chem. 2009 Dec 24;52(24):8047-56. doi: 10.1021/jm901260k.

PMID:
19929003
17.
18.

Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists.

Evindar G, Satz AL, Bernier SG, Kavarana MJ, Doyle E, Lorusso J, Taghizadeh N, Halley K, Hutchings A, Kelley MS, Wright AD, Saha AK, Hannig G, Morgan BA, Westlin WF.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2315-9. doi: 10.1016/j.bmcl.2009.02.073. Epub 2009 Feb 23.

PMID:
19282175
19.

Synthesis and evaluation of alkoxy-phenylamides and alkoxy-phenylimidazoles as potent sphingosine-1-phosphate receptor subtype-1 agonists.

Evindar G, Bernier SG, Kavarana MJ, Doyle E, Lorusso J, Kelley MS, Halley K, Hutchings A, Wright AD, Saha AK, Hannig G, Morgan BA, Westlin WF.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):369-72. doi: 10.1016/j.bmcl.2008.11.072. Epub 2008 Nov 24.

PMID:
19081720
20.

An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis.

Lazarus DD, Doyle EG, Bernier SG, Rogers AB, Labenski MT, Wakefield JD, Karp RM, Clark EJ, Lorusso J, Hoyt JG, Thompson CD, Hannig G, Westlin WF.

Inflamm Res. 2008 Jan;57(1):18-27. doi: 10.1007/s00011-007-7075-5.

PMID:
18209961
21.

Team work in protein processing.

Hannig G.

Chem Biol. 2007 Jul;14(7):732-4.

22.

Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458.

Hannig G, Bernier SG, Hoyt JG, Doyle B, Clark E, Karp RM, Lorusso J, Westlin WF.

Arthritis Rheum. 2007 Mar;56(3):850-60.

23.

A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.

Cooper AC, Karp RM, Clark EJ, Taghizadeh NR, Hoyt JG, Labenski MT, Murray MJ, Hannig G, Westlin WF, Thompson CD.

Clin Cancer Res. 2006 Apr 15;12(8):2583-90.

24.

Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458.

Hannig G, Lazarus DD, Bernier SG, Karp RM, Lorusso J, Qiu D, Labenski MT, Wakefield JD, Thompson CD, Westlin WF.

Int J Oncol. 2006 Apr;28(4):955-63.

PMID:
16525646
25.

Methionine aminopeptidases type I and type II are essential to control cell proliferation.

Bernier SG, Taghizadeh N, Thompson CD, Westlin WF, Hannig G.

J Cell Biochem. 2005 Aug 15;95(6):1191-203.

PMID:
15962312
26.

A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis.

Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF, Hannig G.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10768-73. Epub 2004 Jul 12.

27.

Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules.

Rittershaus CW, Thomas LJ, Miller DP, Picard MD, Geoghegan-Barek KM, Scesney SM, Henry LD, Sen AC, Bertino AM, Hannig G, Adari H, Mealey RA, Gosselin ML, Couto M, Hayman EG, Levin JL, Reinhold VN, Marsh HC Jr.

J Biol Chem. 1999 Apr 16;274(16):11237-44.

28.

Strategies for optimizing heterologous protein expression in Escherichia coli.

Hannig G, Makrides SC.

Trends Biotechnol. 1998 Feb;16(2):54-60.

PMID:
9487731
29.

A tightly regulated high level expression vector that utilizes a thermosensitive lac repressor: production of the human T cell receptor V beta 5.3 in Escherichia coli.

Andrews B, Adari H, Hannig G, Lahue E, Gosselin M, Martin S, Ahmed A, Ford PJ, Hayman EG, Makrides SC.

Gene. 1996 Dec 5;182(1-2):101-9.

PMID:
8982074
30.

Expression of the human T-cell receptor V beta 5.3 in Escherichia coli by thermal induction of the trc promoter: nucleotide sequence of the lacIts gene.

Adari H, Andrews B, Ford PJ, Hannig G, Brosius J, Makrides SC.

DNA Cell Biol. 1995 Nov;14(11):945-50.

PMID:
7576181
31.

Negative regulation of mitosis in fission yeast by catalytically inactive pyp1 and pyp2 mutants.

Hannig G, Ottilie S, Erikson RL.

Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10084-8.

32.

Reversible tyrosine phosphorylation and cell cycle control.

Atherton-Fessler S, Hannig G, Piwnica-Worms H.

Semin Cell Biol. 1993 Dec;4(6):433-42. Review.

PMID:
8305682
33.
34.

The fission yeast genes pyp1+ and pyp2+ encode protein tyrosine phosphatases that negatively regulate mitosis.

Ottilie S, Chernoff J, Hannig G, Hoffman CS, Erikson RL.

Mol Cell Biol. 1992 Dec;12(12):5571-80.

35.

Multiple src-related kinase genes, srk1-4, in the fresh water sponge Spongilla lacustris.

Ottilie S, Raulf F, Barnekow A, Hannig G, Schartl M.

Oncogene. 1992 Aug;7(8):1625-30.

PMID:
1378585
36.

A fission-yeast gene encoding a protein with features of protein-tyrosine-phosphatases.

Ottilie S, Chernoff J, Hannig G, Hoffman CS, Erikson RL.

Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3455-9.

37.

Conservation of structure and expression of the c-yes and fyn genes in lower vertebrates.

Hannig G, Ottilie S, Schartl M.

Oncogene. 1991 Mar;6(3):361-9.

PMID:
1707152
38.

[Measurement of physical capacity in senior sports using motor criteria].

Hannig G.

Aktuelle Gerontol. 1983 Sep;13(5):201-4. German.

PMID:
6139038

Supplemental Content

Loading ...
Support Center